Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology “Methods and Compositions for Oral Administration of Exenatide” has been allowed by the United States Patent and Trademark Office.
Nadav Kidron, CEO of Oramed, stated, “This is another important patent in Oramed’s patent portfolio that protects a key aspect of our breakthrough technology with regards to oral Exenatide. This patent allowance comes as we are completing our phase I study with our ORMD-0901 oral exenatide capsule under an IND in the U.S.”
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).